

Zomedica CEO Interview with Wall Street Analyzer Updates Company Progress and Plans

ANN ARBOR, MI / December 15, 2022 / Zomedica Corp. (NYSE American:ZOM)

("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announces an update interview with the Wall Street Analyzer, and Larry Heaton, Zomedica's Chief Executive Officer.

Juan Costello, Senior Analyst with the Wall Street Analyzer, and Larry Heaton, the Chief Executive Officer for Zomedica addressed various topics related to the Company. Discussion areas included an overview of the Company, its recent Q3 financial results, the new manufacturing and distribution facility in Georgia, recent M&A activities including related products and growth strategies, capitalizing on internal sales, marketing and administrative proficiencies, the MyZomedica portal and its potential future capabilities, key trends within the veterinary industry and the Company's goals to capitalize on them

"At Zomedica we market innovative diagnostic and therapeutic products that enable veterinarians to improve the quality of care for their pet patients, increase the satisfaction of the pet parents, and also provide economic benefits to the practice of veterinary medicine by enhancing workflow, cash flow and profitability," said Mr. Heaton. "Zomedica today is a growth story that is just starting and one that we believe will reward long-term investors."

You can visit The Wall Street Analyzer

(<https://wallstreetanalyzer.com/2022/11/29/zomedica-corp-nyse-american-zom/>) to listen to the full interview.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for equine and companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostic and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

###

Follow Zomedica

- Email Alerts: <http://investors.zomedica.com>
- LinkedIn: <https://www.linkedin.com/company/zomedica>
- Facebook: <https://m.facebook.com/zomedica>

- Twitter: <https://twitter.com/zomedica>
- Instagram: https://www.instagram.com/zomedica_inc

Reader Advisory

Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our

commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

PCG Advisory

Kirin Smith, President

ksmith@pcgadvisory.com

+1 646.823.8656

SOURCE: Zomedica Corp.

View source version on accesswire.com:

<https://www.accesswire.com/731940/Zomedica-CEO-Interview-with-Wall-Street-Analyzer-Updates-Company-Progress-and-Plans>